Collectively, we propose that targeting MS4A4A, either through agonistic means or by enhancing its expression in the brain, could potentially mitigate neuronal hyperactivity and thus effectively slow the progression of AD pathology. This evidence concerns the gene MS4A4A and Alzheimer disease.